Structure, Volume 22

# **Supplemental Information**

## Structural Basis for PI(4)P-Specific Membrane

Recruitment of the Legionella pneumophila

## Effector DrrA/SidM

Claudia M. Del Campo, Ashwini K. Mishra, Yu-Hsiu Wang, Craig R. Roy, Paul A. Janmey, and David G. Lambright

### **Supplemental Figures**



**Figure S1 related to Figure 1 and 4**. Analysis of equilibrium SPR responses for binding to PI(4)P-containing liposomes as a function of protein concentration. (A) Global fit of the quadratic binding model for four independent experiments with DrrA WT. Solid lines represent quadratic binding models with  $K_D$  treated as a global parameter and [PI4P], Rmax, and Rmin treated as local parameters (see also Figure 1B). (B) Fit of the quadratic binding model to WT and tight binding mutants ( $K_D < 50$  nM, filled symbols) and of the Langmuir binding model to weak binding mutants ( $K_D > 200$  nM, open symbols),  $K_D$  values for these mutants are included in Table S2. (C - D) Equilibrium responses and  $K_D$  values for DrrA and the FAPP1 PH domain (FAPP-PH; residues 1-98) fit with the quadratic and Langmuir binding models, respectively, under two different lipid compositions.



**Figure S2 related to Figure 6**. Structure-based membrane targeting model for full length DrrA. A composite model for full length DrrA with nucleotide free Rab1 was constructed and docked with a simulated POPC bilayer as described in the discussion. Rab1-AMP was modeled in a hypothetical orientation in which the AMPylated tyrosine is near the catalytic residues in the ATase domain. The hypervariable C-termini of Rab1 and Rab1-AMP were modeled in arbitrary conformations compatible with membrane insertion of the prenyl groups.

| Protein  | $K_D(\mu M)$        | Reference               |
|----------|---------------------|-------------------------|
| DrrA     | $0.0038 \pm 0.0027$ | This study              |
| Bem1p-PX | $1.2 \pm 0.10$      | (Stahelin et al., 2007) |
| OSBP-PH  | $0.10\pm0.020$      | (Stahelin et al., 2007) |
| GOLPH3   | $2.6 \pm 0.20$      | (Wood et al., 2009)     |
| Vps74    | $8.9 \pm 0.30$      | (Wood et al., 2009)     |
| FAPP1-PH | $0.46\pm0.080$      | (He et al., 2011)       |

Table S1 related to Figure 1. Dissociation constant ( $K_D$ ) for binding of DrrA<sub>321-647</sub> and eukaryotic PI(4)P-binding domains to PI(4)P-containing liposomes determined by SPR

| DrrA <sub>321-647</sub> | $K_{D} \left(\mu M\right)$ * | $K_D$ (arb. units) | Fitted binding model |  |
|-------------------------|------------------------------|--------------------|----------------------|--|
| WT                      | $0.0038 \pm 0.0027$          | 1.0                | Quadratic            |  |
| K568A                   | $9.8 \pm 2.5$                | 2600               | Langmuir             |  |
| R541A                   | $0.77\pm0.086$               | 210                | Langmuir             |  |
| Y532A                   | $0.55\pm0.16$                | 150                | Langmuir             |  |
| Q608R                   | $1.04\pm0.022$               | 280                | Langmuir             |  |
| S620A/S621A             | $0.0095 \pm 0.0019$          | 2.5                | Quadratic            |  |
| T611A/T612A             | $0.031 \pm 0.0090$           | 8.3                | Quadratic            |  |
| L610A                   | $0.014 \pm 0.0023$           | 3.6                | Quadratic            |  |
| L617A                   | $0.023 \pm 0.0028$           | 6.1                | Quadratic            |  |
| L614A/L615A             | $0.34\pm0.058$               | 91                 | Langmuir             |  |
| L610A/L614A/L615A       | $1.7\pm0.29$                 | 440                | Langmuir             |  |
| L610D                   | $0.23\pm0.047$               | 62                 | Langmuir             |  |
| L614D/L615D             | $6.2 \pm 0.16$               | 1600               | Langmuir             |  |

**Table S2 related to Figure 4.** Dissociation constant ( $K_D$ ) for binding of DrrA<sub>321-647</sub> wild type (WT) and mutants to POPC liposomes containing 3% PI(4)P determined by SPR (See also Figure S1B)

\* Values are mean  $\pm$  standard deviation for 2-4 independent experiments.

| Protein           | Κ <sub>D</sub><br>(μΜ) | ΔH<br>(kcal/mol)          | ΔG<br>(kcal/mol) | -TΔS<br>(kcal/mol) | K <sub>D</sub><br>(arb. units) |
|-------------------|------------------------|---------------------------|------------------|--------------------|--------------------------------|
|                   |                        | di-C <sub>4</sub> -PI(4)P |                  |                    |                                |
| WT                | $0.056 \pm 0.011$      | $-31 \pm 1.2$             | $-10 \pm 0.12$   | 21 ± 1.2           | 1                              |
| S620A/S621A       | $5.8 \pm 0.57$         | $-17 \pm 1.0$             | $-7.1 \pm 0.057$ | $10 \pm 0.93$      | 104                            |
| T611A/T612A       | $0.93\pm0.042$         | $-25 \pm 1.4$             | $-8.1 \pm 0.027$ | $17 \pm 1.4$       | 17                             |
| L610A             | $0.064 \pm 0.0057$     | $-34 \pm 0.71$            | $-10 \pm 0.052$  | $24 \pm 0.76$      | 1                              |
| L614A/L615A       | $0.80 \pm 0.11$        | $-28 \pm 1.5$             | $-8.2 \pm 0.076$ | $20 \pm 1.5$       | 14                             |
| L610A/L614A/L615A | $0.60\pm0.092$         | $-31 \pm 2.1$             | $-8.4 \pm 0.091$ | $22 \pm 2.0$       | 11                             |
| L610D             | $0.25\pm0.014$         | $-32 \pm 3.5$             | $-8.9 \pm 0.033$ | $23\pm3.5$         | 4                              |
| L614D/L615D       | 9.5 ± 1.4              | $-33 \pm 4.2$             | $-6.8 \pm 0.088$ | $26\pm4.2$         | 170                            |
| L610D/L614D/L615D | $15 \pm 3.6$           | $-25 \pm 0.00$            | $-6.5 \pm 0.14$  | $19 \pm 0.14$      | 276                            |
|                   |                        | Ins(1,4)P <sub>2</sub>    |                  |                    |                                |
| WT                | 2.1 ± 0.31             | $-28 \pm 4.6$             | $-7.7 \pm 0.12$  | $20 \pm 4.7$       | 1                              |
| T611A/T612A       | $140 \pm 30$           | $-28 \pm 0.71$            | $-5.2 \pm 0.12$  | $22 \pm 0.83$      | 69                             |
| L610A             | $2.1 \pm 0.064$        | $-28 \pm 0.00$            | $-7.7 \pm 0.017$ | $20\pm0.017$       | 1                              |
| L614A/L615A       | $18 \pm 0.71$          | $-28 \pm 0.71$            | $-6.4 \pm 0.024$ | $21\pm0.73$        | 9                              |
| L610A/L614A/L615A | $13 \pm 0.85$          | $-29 \pm 0.71$            | -6.6 ± 0 .038    | $22 \pm 0.67$      | 6                              |
| L610D             | 9.7 ± 2.1              | $-25 \pm 3.5$             | $-6.8 \pm 0.13$  | $18 \pm 3.7$       | 5                              |

**Table S3 related to Figure 4.** Thermodynamic analysis of  $DrrA_{321-647}$  wild type (WT) and mutants binding to the soluble analogs di-C<sub>4</sub>-PI(4)P and  $Ins(1,4)P_2$  determined by  $ITC^{\$}$ 

<sup>§</sup> Values are mean  $\pm$  standard deviation 2-3 independent measurement. No heat was detected for binding of dibutyl-PI(4)P to K568A, Y532A, and R541A.

#### **Supplemental Experimental Procedures**

#### Materials

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-Phospholipids, palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) were from Avanti, di-C<sub>16</sub>phophatidyl-inositol-polyphosphates from Cell Signals, dibutanoyl-phosphatidyl-inositol-4-phosphate (dibutyl PI(4)P) and D-myo-inositol 1,4-bisphosphate ( $Ins(1,4)P_2$ ) from Echelon. For membrane insertion studies, natural  $PI(4,5)P_2$  (porcine brain L- $\alpha$ phosphatidyl-inositol-4,5-bisphosphate) and neutral phospholipids such as DOPC (1,2dioleoyl-sn-glycero-3-phosphocholine) and Rho-DOPE (1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)) were from Avanti. Phosphatidylinositol-4-phosphate diC16 (PI(4)P diC16) was from Echelon Biosciences. The concentrations of unlabeled lipid stock solutions were routinely monitored by a phosphorus assay (Rouser et al., 1970). Subphase reagents 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), ethylenediamine-tetraacetic acid (EDTA), CaCl<sub>2</sub>, and KCl were from Fisher Scientific.

#### **Constructs, Expression and Purification**

Constructs were amplified with Vent polymerase and ligated into a modified pET15b vector incorporating an N-terminal 6×His tag (MGHHHHHHGS). Site-specific mutants were generated with the QuickChange II XL kit (Stratagene). Wild type and mutated constructs were confirmed by sequencing. Constructs were expressed in BL21(DE3)RIPL cells (Stratagene) cultured in  $2 \times YT$ -amp (16 g tryptone, 10 g yeast extract, 5 g NaCl, and 100 mg ampicillin per liter) at  $37^{\circ}C$  to an OD<sub>600</sub> of 0.2, then at

21°C to an OD<sub>600</sub> of 0.4, and induced with 50 mM IPTG for 16 h. Cells resuspended in lysis buffer (50 mM Tris, pH 8.0, 0.1M NaCl, 0.1% 2-mercaptoethanol) were disrupted by sonication in the presence of 0.1 mM PMSF, 0.2 mg/ml lysozyme, and 0.01 mg/ml protease free DNase I (Worthington). Lysates were supplemented with 0.5% Triton X-100 and centrifuged at  $35,000 \times g$  for 1 h. Supernatants were added to Ni-NTA-Sepharose (GE Healthcare) equilibrated with lysis buffer and nutated for 15 min at 4°C. The beads were washed extensively with buffer containing 50 mM Tris, pH 8.0, 50 mM imidazole, 0.5 M NaCl, and 0.1% 2-mercaptoethanol. Proteins were eluted with 300 mM imidazole and further purified by ion exchange on HiTrap S or Q (GE Health Care) with gradients of 0-1M NaCl, followed by gel filtration on Superdex-75 (GE Health Care).

#### **Supplemental References**

Rouser, G., Fleische.S, and Yamamoto, A. (1970). Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids *5*, 494-6.